IPM Take
Cancer is moving back into EU budget politics. The issue is no longer whether Europe’s Beating Cancer Plan is popular. The issue is whether its implementation survives the next long-term budget, with enough funding for screening, workforce, oncology data systems, specialised care, clinical trials and survivor protections. For personalised oncology, political commitment only matters if it becomes durable infrastructure.
Executive Summary
On 12 February 2026, the European Parliament adopted a World Cancer Day resolution calling for renewed EU political commitment, funding and coordination to support the full implementation of Europe’s Beating Cancer Plan. MEPs called for a dedicated EU health programme in the 2028 to 2034 long-term budget, fair and timely access to cancer medicines and innovative therapies, easier cross-border access to specialised care and clinical trials, especially for rare and complex cancers, and stronger “right to be forgotten” protections for cancer survivors.
Why it matters
- Policymakers: Need to keep cancer visible in the next EU budget, especially if health funding is folded into broader financial envelopes.
- Patients / advocates: Should track whether political commitments translate into access, cross-border care, clinical trial routes and survivor protections.
- Hospitals / providers: May face stronger expectations to support screening, specialised care, oncology data systems and cross-border referral pathways.
Before this resolution, Europe’s Beating Cancer Plan had already created a strong policy framework, but its future depended on continued funding and political ownership. The Parliament text makes that tension explicit: cancer policy is now tied to the next EU budget cycle.
What has changed is the framing. MEPs are not only asking for better prevention or treatment. They are asking for predictable investment in cancer infrastructure, including vaccination and screening programmes, workforce development, oncology data systems, access to innovative therapies, and cross-border care for rare and complex cancers.
For personalised medicine, the signal is clear. Rare and complex cancers, molecular testing, specialised referral and clinical trial access cannot be delivered evenly if Europe treats cancer as a temporary priority. Implementation needs stable policy machinery, not only political attention around World Cancer Day.
